Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

Summary Bruton tyrosine kinase inhibitors (BTKi) have transformed the therapeutic landscape of chronic lymphocytic leukaemia (CLL) and non‐Hodgkin lymphoma. However, primary and acquired resistance to BTKi can be seen due to a variety of mechanisms including tumour intrinsic and extrinsic mechanisms such as gene mutations, activation of bypass signalling pathways and tumour microenvironment. Herein, we provide an updated review of the key clinical data of BTKi treatment in CLL, mantle cell lymphoma, and diffuse large B‐cell lymphoma (DLBCL). We incorporate the most recent findings regarding mechanisms of resistance to covalent and non‐covalent inhibitors, including ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib. We also cover the clinical sensitivity of certain molecular subtypes of DLBCL to an ibrutinib‐containing regimen. Lastly, we summarise ongoing clinical investigations aimed at overcoming resistance via use of BTKi‐containing combined therapies or the novel non‐covalent BTKi. The review article targets an audience of clinical practitioners, clinical investigators and translational researchers.